Table 4.

Association of antiphospholipid assays with venous thrombosis.

AssayThrombosis, n = 103 No. (% positive)No Thrombosis, n = 223 No. (% positive)OR 95% CI*p (adjusted)*
IgGAnti-ß2-GPI15 (15)9 (4)3.7 (1.5, 9.1)0.0048
Anti-ß2-GPI D19 (9)11 (5)1.7 (0.7, 4.2)0.29
aCL17 (17)21 (9)1.7 (0.8, 3.5)0.14
Anti-PS/PT21 (20)19 (9)2.7 (1.3, 5.8)0.0082
IgMAnti-ß2-GPI6 (6)11 (5)1.1 (0.4, 3.1)0.88
aCL13 (13)20 (9)1.4 (0.7, 3.1)0.36
Anti-PS/PT27 (26)41 (18)1.5 (0.8, 2.6)0.19
IgAAnti-ß2-GPI31 (30)41 (18)1.9 (1.1, 3.3)0.024
aCL8 (8)4 (2)4.3 (1.2, 14.8)0.023
Anti-ß2-GPI D4/520 (19)43 (19)1.0 (0.6, 1.9)0.97
IgG/MAnti-PS/PT29 (28)33 (15)2.1 (1.2, 3.8)0.015
LAC**dRVVT36 (41)35 (18)3.3 (1.8, 6.0)< 0.0001
  • * Adjusted for age, sex, and ethnicity.

  • ** Forty-three patients did not have dilute Russell viper venom test (dRVVT) results available. Thus, the total number of patients for the thrombosis group was 88, and the no-thrombosis group, 195. Anti-ß2-GPI: anti-ß2-glycoprotein I; anti-ß2-GPI D1: anti-ß2-glycoprotein I domain 1; aCL: anticardiolipin; anti-PS/PT: antiphosphatidylserine/prothrombin; LAC: lupus anticoagulant; anti-ß2-GPI D4/5: anti-ß2-glycoprotein I domain 4/5.